

Literature and news reports

Thomson Pharma gives you access to comprehensive literature and news reports that contain premium information pulled from a wide range of sources. You can generate literature and news reports by using one of the many search options available on *Thomson Pharma*. You also can link to literature and news reports via the content delivered directly to your personalized home page or via a report focusing on a different area of content, such as a drug report, an intellectual property report, or a target report.

The tabbed report makes it easier to find associated information.

Literature and news portlets

You can set up your *Thomson Pharma* home page so that it is constantly updated with the latest literature and news coverage. This means you can be alerted whenever new or updated literature and news information becomes available within *Thomson Pharma*, helping you stay informed about the latest developments in your field.

Through the portlets on your personalized home page, you can:

- Receive daily updates of the latest journal articles
- View rolling selected feature articles and link to the full article
- View the latest news headlines with links to the full stories
- Hear about the latest meetings and conferences in your field with links to specially-written reports
- Keep up-to-date with up to 60 key drug development journals and four critical review journals
- View new synthetic methods from leading organic chemistry journals

Find out more at:
thomsonpharma.com



For further information, please contact your regional Thomson Scientific office.

Thomson Scientific Regional Head Offices:

Americas

Phone +1 800 336 4474
+1 215 386 0100

Europe, Middle East and Africa

Phone +44 20 7433 4000

Japan

Phone +81 3 5218 6500

Asia Pacific

Phone +65 6879 4118

Thomson Scientific Offices around the World:

Sydney, Australia
Rio de Janeiro, Brazil
Paris, France
Munich, Germany
Hong Kong
Bangalore, India
Tokyo, Japan
Mexico City, Mexico
Beijing, People's Republic of China
Seoul, Republic of Korea
Singapore
Taipei, Taiwan
London, United Kingdom
USA
Alexandria, Virginia
Ann Arbor, Michigan
Carlsbad, California
San Jose, California
East Haven, Connecticut
Lisle, Illinois
Portland, Maine
Horsham, Pennsylvania
Philadelphia, Pennsylvania

For complete contact information, visit:
scientific.thomson.com/contact

DRUGS

INTELLECTUAL
PROPERTY

► LITERATURE
& NEWS

COMPANIES

TARGETS

CHEMISTRY

SEQUENCES



THOMSON Pharma®



Thomson Pharma® is a dynamic information solution for the pharmaceutical and biotechnology industries. It features the best scientific, patent, and financial content offered by Thomson businesses. This premium content has been enhanced with powerful search tools and integrated into a single solution that professionals working at all stages of drug development can personalize to suit their needs.

Critical information from journals, conferences, and news stories

Through *Thomson Pharma*, you can access multiple types of content, including critical pharmaceutical, biotechnology, and chemistry information drawn from journals, conferences, and news stories. Through a single platform, you can access cutting-edge information from the most authoritative research literature in the world and benefit from extensive coverage of the latest conferences and the most recent news stories and press releases. You can keep up to date with the latest developments in your field and obtain a complete picture of today's global research.

Through *Thomson Pharma*, you can:

- Browse **tables of contents, bibliographic information, and author abstracts** from recently-published issues of the world's leading scholarly journals
- Search scientific literature using index terms developed by four world leading information systems and brought together for the first time in *Thomson Pharma*
- Scan drug, company, and scientific news headlines and link to both the full story and the full text of the original press release
- Review news articles written and placed in context by a team of experts
- View **information on newly-reported meetings and conferences** and link to specially-written reports
- Learn about forthcoming meetings and link to associated Web sites
- Conveniently access **original source documents**, including full-text journal articles and **full-text Web documents**
- Read evaluated **drug literature reviews**
- Discover key **chemical reactions and compound data** published in global literature
- Set up alerts that keep you updated with the latest literature results
- Export bibliographic data into the leading bibliographic management tools

Literature reports

Literature & News Report

OVERVIEW CHEMISTRY MMS

SUMMARY ABSTRACT EXTENDED ABSTRACT NEWS STORY FULL TEXT RELATED COMPANY NEWS COMMENTS INDEXING

SUMMARY

Title Disocyanate asthma and gene-environment interactions with IL4RA, CD-14, and IL-13 genes

Source ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY 2006, 97 (800-806)

Authors Bernstein, DJ; Wang, N; Campo, P; Chakraborty, R; Smith, A; Cartier, A; Boulet, LP; Malo, JL; Yucsoy, B; Luster, M; Tarlo, SM; Hershey, GKK

Address Hershey, GKK, Childrens Hosp, Med Ctr, Sept Pediat, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA

Citations [Cited references: 52](#)
[Times cited: 1](#)
[Total cited & citing combined: 53](#)
[Find Related Records](#)

High-quality summary of the journal article, specially-written by editorial experts and focusing on the pharmacological and biotechnological content.

Original abstract written by the author(s) of the journal article.

Title and volume number of the journal in which the article was published.

The original author title of the journal article or press release.

Full address to write to for a reprint of the original article.

ACTION DETAILS

Reaction Overview

(S)-((eta(6)-p-Cymene)(eta(6)-C₆Me₆)(eta(6)-C₆H₅(CH(NH-CO₂Et)CH₂OCOCH(CH₃)₂))Ru₃(mu(2)-H)₃(mu(3)-O))BF₄

H₂

H₂O

49.35 ATM

48.0 HR

25.0 DEG C

autoclave

Reaction Summary

[Reaction Details](#)
[View Mol File](#)

Discover key chemical reactions and compound data published in global literature. Links direct to chemistry reports.

Search scientific literature using index terms developed by four leading information systems and brought together for the first time in Thomson Pharma.

INDEXING

WOS/Current Contents Connect (ISI)

Author Keywords: -

Keywords Plus: ARENE RUTHENIUM COMPLEXES; BENZENE HYDROGENATION CATALYSIS; HETEROGENEOUS CATALYSIS; ABSOLUTE-CONFIGURATION; TRIRUTHENIUM CLUSTER; ENANTIOMERIC PURITY; MOLECULAR-STRUCTURE; AQUEOUS-SOLUTION; OPTICAL-ACTIVITY; SF6COM CLUSTERS

Look up a journal title.

Browse journals by therapy area.

Link to table of content for specific issues.

Browse Journals

Look up a Journal name

Select a Therapy Area to browse relevant journals

- Cancer/Neoplasm
- Cardiovascular
- Dermatology
 - ACTA DERMATO-VENEREOLOGICA
 - AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
 - 2003, Vol. 4
 - 2004, Vol. 5
 - 2005, Vol. 6
 - 2006, Vol. 7
 - 2007, Vol. 8
 - [Iss. 1](#)
 - [Iss. 2](#)
 - AMERICAN JOURNAL OF DERMATOPATHOLOGY
 - ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
 - ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
 - ARCHIVES OF DERMATOLOGICAL RESEARCH
 - ARCHIVES OF DERMATOLOGY
 - BRITISH JOURNAL OF DERMATOLOGY
 - BURNS

News reports

Literature & News Report

OVERVIEW CHEMISTRY NMR

SUMMARY ABSTRACT EXTENDED ABSTRACT NEWS STORY FULL TEXT RELATED COMPANY NEWS COMMENTS INDEXING

NEWS SUMMARY

News Title ImmuneRegen's Viprovex improves efficacy of flu drugs and vaccines

Original Title ImmuneRegen BioSciences, Inc. and Virion Systems, Inc. Continue Testing Viprovex(R) and Tamiflu(R) as Possible Influenza Co-Treatment

Source Press Release 2007, July 19

Authors ImmuneRegen BioSciences Inc

Categories Preclinical & research

Full text links [LINKS](#)

Cited in Drug [pan-influenza virus vaccine, GenPhar \(20 Jul 2007\)](#) ; [tamiflura \(20 Jul 2007\)](#) ; [oseltamivir \(03 Jul 2007\)](#)

NEWS STORY [1](#)

ImmuneRegen BioSciences' Viprovex improves the efficacy of GenPhar's influenza vaccine, and Gilead Sciences and Roche Holdings'

Find out more about the company with direct link to company report.

Link to individual news reports.

Link directly to relevant drug report.

Link to additional reports this reference has also been cited in.

FULL TEXT [1](#)

JPRNewsWire -- ImmuneRegen's Viprovex(R) Shows Adjuvant Activity with Avian Influenza Vaccines and Decreases Lung Symptoms in Animals Exposed to Influenza Virus and Treated with Tamiflu(R)

SCOTTSDALE, Ariz., July 19 (JPRNewsWire-FirstCall) -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc., today announced adjuvant activity of its immunomodulator, Viprovex(R) when administered in conjunction with peptide vaccines in development at GenPhar Incorporated. Additional preliminary results from pre-clinical tests in animal models on Viprovex(R) in conjunction with Tamiflu(R) (Roche's FDA-approved influenza prophylactic and treatment) show that treated subjects with both Viprovex and Tamiflu protect lungs against the dangerous influenza virus.

Conveniently access original source documents, including full-text journal articles and full-text Web documents.

RELATED COMPANY NEWS [1](#)

The adjuvant studies examined GenPhar Inc. These previously breath of neutralizing activity is

Other Recent news about [Gilead Sciences Inc](#)
[Financial results](#)

Other Recent news about [Roche Holding AG](#)
[Financial results](#)
[Appointments](#)
[Roche begins phase II psoriasis trial of BICX-4208](#)

Meeting reports

Literature & News Report

OVERVIEW CHEMISTRY NMR

SUMMARY ABSTRACT EXTENDED ABSTRACT NEWS STORY FULL TEXT RELATED COMPANY NEWS COMMENTS INDEXING

MEETING SUMMARY

Meeting Title Advances in the Molecular Pharmacology and Therapeutics for Bone Disease, Oxford, UK, 10-11 July 2007

Source IDdb Meeting Report 2007, July 10-11

Authors Bouillon R

Categories Meeting reports

Full text links [LINKS](#)

Cited in Drug [denosumab \(17 Jul 2007\)](#)

ABSTRACT [1](#)

The 2-day Advances in the Molecular Pharmacology and Therapeutics for Bone Disease meeting, organized by the Botnar Research Centre, reviewed preclinical and early clinical studies on new bone therapeutics, and included sessions on cellular regulation of bone homeostasis and bone imaging, as well as functional genomics. Bone anabolic or potentially bone anabolic agents such as parathyroid hormone (PTH), nuclear receptor modulators and several targets within the wnt signaling pathway, including sclerostin, and the RANK-RANKL system were extensively reviewed.

FULL TEXT [1](#)

Introduction
 The 2-day Advances in the Molecular Pharmacology and Therapeutics for Bone Disease meeting, organized by the Botnar Research Centre, reviewed preclinical and early clinical studies on new bone therapeutics, and included sessions on cellular regulation of bone homeostasis and bone imaging, as

The original meeting title.

Name(s) of all authors associated with report.

Original abstract, written by the author reporting on the meeting.

Full text from the original meeting press release.